Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 11—November 2006
Dispatch

Molecular Characterization of Tickborne Relapsing Fever Borrelia, Israel

Author affiliations: *Ministry of Health, Jerusalem, Israel; †Hebrew University–Hadassah Faculty of Medicine, Jerusalem, Israel

Cite This Article

Abstract

Blood samples from 18 tickborne relapsing fever (TBRF) patients and Ornithodoros tholozani specimens were tested with a Borrelia flaB-PCR. Results were positive for all patients and 2%–40% of ticks. A 7–amino acid gap characterized all 9 sequenced flagellin gene amplicons. By phylogenetic analysis, Israel TBRF Borrelia sequences clustered separately from American and African groups.

Tickborne relapsing fever (TBRF) is caused by Borrelia species and is transmitted to humans by Ornithodoros soft ticks. Worldwide, a dozen Borrelia species are known to cause this disease (1). In Israel, TBRF is considered to be caused by Borrelia persica and transmitted by the cave tick Ornithodoros tholozani (1). This tick and TBRF are distributed through Central Asia (2) and the Middle East (1). Other Borrelia species that cause TBRF have been described in Iran (3), but their precise range of distribution is not known.

In Israel, from 1980 through 2002, 184 cases of TBRF were reported among the civilian population (8 cases/year), and 88% of the case-patients were infected in caves (4). Among military personnel, TBRF incidence averages 6.4 cases/100,000 persons (5). In Jordan, an average of 72 civilian cases per year was reported from 1959 through 1969 (6). In Iran, an average of 100 cases per year has been recently reported (7).

TBRF in Israel was first reported by Nicholson (8) at the time World War I. Detailed clinical and epidemiologic features of the disease are well described in this article, particularly the transmission by ticks (8). However, Nicholson incorrectly attributed the disease to the soft tick Argas persicus. In 1937, Adler et al. clearly identified O. papillipes (tholozani) as the vector of the disease (9) and characterized the causative agent as Spirochaeta persica (10).

Although American (11) and African TBRF Borrelia (12) are now better characterized, no definitive molecular characterization of Borrelia species responsible for relapsing fever has been achieved in Israel. The aim of this study is to provide initial molecular characterization of the etiologic agent of TBRF in Israel from both ticks and human samples and to compare it with previously described agents of TBRF in other parts of the world.

The Study

Figure 1

Thumbnail of Ornithodoros tholozani ventral (A) and dorsal (B) views.

Figure 1. Ornithodoros tholozani ventral (A) and dorsal (B) views.

We designed a genus-specific set of primers (BOR1: 5´ TAA TAC GTC AGC CAT AAA TGC 3´ and BOR2: 5´ GCT CTT TGA TCA GTT ATC ATT C 3´) that targeted the Borrelia flaB flagellin gene (13). Each PCR mixture (25 μL) contained 3 μL of target DNA and was subjected to 1 min at 95°C, followed by 40 cycles of 56°C for 30 sec, 72°C for 30 sec, 94°C for 30 sec, and 5 min at 72°C for final elongation. DNA of B. duttonii and B. burgdorferi sensu stricto (strain B31) was used as controls. DNA of blood and ticks was extracted with the DNA easy tissue kit (Qiagen, Hilden, Germany). Tick samples were collected by using CO2 traps in caves and were identified as Ornithodoros tholozani (Figure 1) by the Entomology Laboratory (Ministry of Health, Jerusalem). The tick specimens collected were tested either individually or as pools. Of 184 tick specimens collected from 5 different areas (Table 1), 94 were tested by BOR1-BOR2 PCR. One pool of 5, a pool of 4, and 6 individual specimens were positive; all produced a unique band 750 bp in length. The percentage of tick infection was variable, ranging from <2% in Ma'ale-Adumim to 40% in the Be'er Sheva region.

For patients, the TBRF diagnosis was established as previously reported (5). Eighteen samples of human blood were sent to the Parasitology Reference Center (Ministry of Health, Jerusalem); the samples corresponded to 15 confirmed cases (positive blood smear) and 3 associated cases of TBRF (negative blood smear). On receipt at the laboratory, fresh human blood samples were examined by darkfield microscopy for viable Borrelia and, if detected, 200 μL of blood was injected into 10-mL vials of BSK-H medium (14) and into 10-week-old ICR mice by the intraperitoneal route. In 4 patients, blood examined by darkfield microcopy showed 1–5 motile Borrelia per slide. In vitro cultivation was unsuccessful. However, Borrelia (1–5/field) were detected on day 4 (twice) and day 6 (twice) in the blood of mice injected intraperitoneally with patient blood. Cultivation attempts from positive mice blood were also unsuccessful. In contrast, all the samples were found positive by BOR1-BOR2 PCR, showing a unique band of 750 bp (data not shown).

PCR products were cloned in T7 plasmid by pGEM-T Easy vector SystemII (Promega, Madison, WI, USA). Plasmids containing inserts were purified and sent for 2-strand sequencing. Direct sequencing of DNA amplified by the BOR1 and BOR2 primers was performed later.

Phylogenetic and molecular evolutionary analyses were conducted by using MEGA version 3.1 (15). Among published flaB genes of TBRF Borrelia strains, only sequences for which a translated protein existed were taken in account. Because of the large number of available sequences for American Borrelia associated with TBRF, as well as for B. duttonii and B. recurrentis, a single sequence representative of each cluster was chosen for taxonomic analyses.

Three PCR amplicons (from 1 tick and 2 human samples) were sequenced after cloning, whereas 6 amplicons (from 2 ticks and 4 human samples) were analyzed by direct sequencing. These 9 sequenced samples showed 98%–100% homology between them and could be divided into 3 groups. The same DNA sequence was found in tick TG52 and in blood from 2 patients, HumanBlood2 and HumanBlood4. These 3 sequences had an additional triplet at the position 627. The second group of sequences, which consisted of tick samples TGd1 and CBkc7 and blood samples C1025B, FL1, and HumanBlood3, were identical, with only 3 minor substitutions between them. The third group consisted of the HumanBlood1 sample.

Figure A1

Thumbnail of CLUSTAL W multiple alignment of 9 Israeli tickborne relapsing fever sequences (bold letters indicate variable amino acid positions as shown in Table 2). The GenBank accession numbers for nucleotide sequences of Borrelia persica flaB shown here are as follows: HumanBloodFL1 (DQ673617), HumanBloodC1015B (DQ679904), OtholozaniCBkc7 (DQ679905), HumanBlood1 (DQ679906), HumanBlood2 (DQ679907), HumanBlood3 (DQ679908), HumanBlood4 (DQ679909), OtholozaniTG52 (DQ679910) and OtholozaniTGd1 (DQ

Figure A1. CLUSTAL W multiple alignment of 9 Israeli tickborne relapsing fever sequences (bold letters indicate variable amino acid positions as shown in Table 2). The GenBank accession numbers for...

All the translated sequenced amplicons showed a very specific signature by the presence of a 7–amino acid (aa) gap at position 216 (Figure A1) when compared with previously described TBRF Borrelia flaB genes. In addition, the local TBRF Borrelia sequences could be grouped into 3 subtypes, according to variation at 7-aa positions (Table 2).

Figure 2

Thumbnail of Phylogenetic tree based on flaB nucleotide sequences. The tree was constructed by the neighbor-joining method in a pairwise deletion procedure. Distances were calculated according to the Jukes and Cantor method. Numbers at nodes correspond to the percentage confidence level in a bootstrap test performed on 1,000 replicates. The scale bar corresponds to a 0.01 distance. The GenBank accession numbers for nucleotide sequences of Borrelia persica flaB shown here are as follows: HumanBlo

Figure 2. Phylogenetic tree based on flaB nucleotide sequences. The tree was constructed by the neighbor-joining method in a pairwise deletion procedure. Distances were calculated according to the Jukes and Cantor method. Numbers...

Comparison with published flaB protein sequences of TBRF Borrelia showed 88%–90% homology with B. duttonii and B. recurrentis, 85%–90% with B. crocidurae, 86%–88% with B. turicatae, 87%–89% with B. hermsii, and 85%–88% with B. parkeri. The sequences of the Israel TBRF Borrelia isolated from different samples clearly clustered in a separate group from the American and the African TBRF species (Figure 2).

Conclusions

Our results suggest that infection rates differ according to location, despite the small number of ticks tested and the use of pools. BOR1-BOR2 PCR was more sensitive than blood smear examination (100% vs 83%). An identical DNA sequence was found in both tick and patient samples and thus confirms, at the molecular level, the role of O. tholozani as the vector of TBRF in Israel.

A signature (7-aa gap) of the flaB flagellin defined the Israeli TBRF sequences as a homologous group different from other TBRF species. Despite the small number of samples studied, a clear polymorphism existed also at the protein level, resulting in 3 local types. This diversity can be explained by the use of direct sequencing of samples rather than through cultivation that reduces the biodiversity of isolates by selecting the most successful in vitro clone.

This study opens a new avenue in TBRF Borrelia studies by demonstrating a Middle East cluster in addition to the American and African groups. These results open encouraging perspectives for the better understanding of entomologic, epidemiologic, and bacteriologic aspects of this disease and may contribute to better diagnosis and treatment.

Dr Assous is head of the Parasitology Reference Laboratory at the Central Laboratories of the Ministry of Health and an associate researcher in the Department of Clinical Microbiology, Hebrew University–Hadassah Faculty of Medicine, Jerusalem. He is on sabbatical leave from the Faculté de Médecine Université de Paris 5, where he has conducted research on Lyme borreliosis for 20 years.

Top

Acknowledgments

We are indebted to Vered Agmon for initiating and promoting the study on TBRF in Israel; to Guy Baranton for his expert help on the phylogenic and taxonomic analysis of the data; and to Zalman Greenberg for his book: Medical and Veterinary Entomological Research in Israel (1838–1989), from which we found all the historical references on TBRF. We are also grateful to the Medical Corps of the Israeli Defense Forces for providing ticks from the Arad Valley region, to Kosta Y. Mumcuoglu for providing ticks from Makoh, and to Heather Schnur for tick identification and editing of the manuscript.

This study was funded in part by a Ministry of Environment grant (Borrelia 804-2) entitled: "Detection of infected populations of Ornithodorus tholozani with Borrelia persica."

Top

References

  1. Parola  P, Raoult  D. Ticks and tickborne bacterial diseases in humans: an emerging infectious threat. Clin Infect Dis. 2001;32:897928. DOIPubMedGoogle Scholar
  2. Kalra  SL, Rao  KN. Observations on the epidemiology of relapsing fever in Kashmir. Indian J Med Res. 1951;39:31321.PubMedGoogle Scholar
  3. Karimi  Y, Hovind-Hougen  K, Birch-Andersen  A, Asmar  M. Borrelia persica and B. baltazardi sp. nov.: experimental pathogenicity for some animals and comparison of the ultrastructure. Ann Microbiol (Paris). 1979;130B:15768.PubMedGoogle Scholar
  4. Wilamowski  A, Assous  M, Anis  E, Marva  E. Tick-Borne relapsing fever in the civilian population of Israel, 1980–2002. In: Lee C-Y, Robinson WH, editors. Proceedings of the Fifth International Conference on Urban Pests, Singapore, July 10–13, 2005. Penang (Malaysia): Perniagaan Ph'ng @ P& Y Design Network; 2005. p. 399–407.
  5. Sidi  G, Davidovitch  N, Balicer  RD, Anis  E, Grotto  I, Schwartz  E. Tickborne relapsing fever in Israel. Emerg Infect Dis. 2005;11:17846.PubMedGoogle Scholar
  6. De Zulueta  J, Nasrallah  S, Karam  JS, Anani  AR, Sweatman  GK, Muir  DA. Finding of tick-borne relapsing fever in Jordan by the Malaria Eradication Service. Ann Trop Med Parasitol. 1971;65:4915.PubMedGoogle Scholar
  7. Arshi  S, Majidpoor  A, Sadeghi  H, Asmar  M, Emdadi  D, Derakhshan  MH. Relapsing fever in Ardabil, a northwestern province of Iran. Arch Iran Med. 2002;5:1415.
  8. Nicholson  FD. Tick fever in Palestine. BMJ. 1919(Dec 20):811.
  9. Adler  S, Theodor  O, Schieber  H. Observations on tick-transmitted human spirochaetosis in Palestine. Ann Trop Med Parasitol. 1937;31:2535.
  10. Adler  S, Ashbel  R. Relapsing fever in Palestine. Medical Leaves. 1939;2:734.
  11. Schwan  TG, Raffel  SJ, Schrumpf  ME, Policastro  PF, Rawlings  JA, Lane  RS, Phylogenetic analysis of the spirochetes Borrelia parkeri and Borrelia turicatae and the potential for tick-borne relapsing fever in Florida. J Clin Microbiol. 2005;43:38519. DOIPubMedGoogle Scholar
  12. Scott  JC, Wright  DJ, Cutler  S. Typing African relapsing fever spirochetes. Emerg Infect Dis. 2005;11:17229.PubMedGoogle Scholar
  13. Picken  RN. Polymerase chain reaction primers and probes derived from flagellin gene sequences for specific detection of the agents of Lyme disease and North American relapsing fever. J Clin Microbiol. 1992;30:99114.PubMedGoogle Scholar
  14. Pollack  RJ, Telford  SR III, Spielman  A. Standardization of medium for culturing Lyme disease spirochetes. J Clin Microbiol. 1993;31:12515.PubMedGoogle Scholar
  15. Kumar  S, Tamura  K, Nei  M. MEGA3 Integrated Software for Molecular Evolutionary Analysis and sequence alignment. Brief Bioinform. 2004;5:15063. DOIPubMedGoogle Scholar

Top

Figures
Tables

Top

Cite This Article

DOI: 10.3201/eid1211.060715

Table of Contents – Volume 12, Number 11—November 2006

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Marc Victor Assous, Government Central Laboratories, Yaakov Eliav St 9, Jerusalem 94467, Israel

Send To

10000 character(s) remaining.

Top

Page created: October 17, 2011
Page updated: October 17, 2011
Page reviewed: October 17, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external